Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

The scent fingerprint of hepatocarcinoma: in-vitro metastasis prediction with volatile organic compounds (VOCs).

Amal H, Ding L, Liu BB, Tisch U, Xu ZQ, Shi DY, Zhao Y, Chen J, Sun RX, Liu H, Ye SL, Tang ZY, Haick H.

Int J Nanomedicine. 2012;7:4135-46. doi: 10.2147/IJN.S32680. Epub 2012 Jul 30.

2.

The screening of volatile markers for hepatocellular carcinoma.

Qin T, Liu H, Song Q, Song G, Wang HZ, Pan YY, Xiong FX, Gu KS, Sun GP, Chen ZD.

Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2247-53. doi: 10.1158/1055-9965.EPI-10-0302.

3.

Comparison of volatile organic compounds from lung cancer patients and healthy controls-challenges and limitations of an observational study.

Schallschmidt K, Becker R, Jung C, Bremser W, Walles T, Neudecker J, Leschber G, Frese S, Nehls I.

J Breath Res. 2016 Oct 12;10(4):046007.

PMID:
27732569
4.

Volatile biomarkers from human melanoma cells.

Kwak J, Gallagher M, Ozdener MH, Wysocki CJ, Goldsmith BR, Isamah A, Faranda A, Fakharzadeh SS, Herlyn M, Johnson AT, Preti G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Jul 15;931:90-6. doi: 10.1016/j.jchromb.2013.05.007. Epub 2013 May 22.

PMID:
23770738
5.

A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions.

Xu ZQ, Broza YY, Ionsecu R, Tisch U, Ding L, Liu H, Song Q, Pan YY, Xiong FX, Gu KS, Sun GP, Chen ZD, Leja M, Haick H.

Br J Cancer. 2013 Mar 5;108(4):941-50. doi: 10.1038/bjc.2013.44.

6.

Investigation of lung cancer biomarkers by hyphenated separation techniques and chemometrics.

Buszewski B, Ulanowska A, Kowalkowski T, Cieśliński K.

Clin Chem Lab Med. 2011 Oct 28;50(3):573-81. doi: 10.1515/CCLM.2011.769.

PMID:
22035139
7.

The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines.

Wang Y, Hu Y, Wang D, Yu K, Wang L, Zou Y, Zhao C, Zhang X, Wang P, Ying K.

Cancer Biomark. 2012;11(4):129-37. doi: 10.3233/CBM-2012-00270.

PMID:
23144150
8.

Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition.

Zhu K, Dai Z, Pan Q, Wang Z, Yang GH, Yu L, Ding ZB, Shi GM, Ke AW, Yang XR, Tao ZH, Zhao YM, Qin Y, Zeng HY, Tang ZY, Fan J, Zhou J.

Clin Cancer Res. 2011 Dec 1;17(23):7294-302. doi: 10.1158/1078-0432.CCR-11-1327. Epub 2011 Oct 5.

9.

[Effects of high metastatic potential hepatocellular carcinoma cell-binding peptide on the invasion and metastasis of liver cancer].

Jia WD, Wang W, Tang ZY, Xu GL, Sun HC, Zhou HJ.

Zhonghua Zhong Liu Za Zhi. 2009 Apr;31(4):241-5. Chinese.

PMID:
19615273
10.

Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.

Lei X, Li YF, Chen GD, Ou DP, Qiu XX, Zuo CH, Yang LY.

Oncotarget. 2015 Dec 1;6(38):40622-41. doi: 10.18632/oncotarget.5872.

11.

Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma.

Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, Huang XW, Fan J, Zhou J.

Hepatology. 2012 Dec;56(6):2242-54. doi: 10.1002/hep.25907.

PMID:
22711685
12.

Gas chromatography/time-of-flight mass spectrometry-based metabonomics of hepatocarcinoma in rats with lung metastasis: elucidation of the metabolic characteristics of hepatocarcinoma at formation and metastasis.

Li ZF, Wang J, Huang C, Zhang S, Yang J, Jiang A, Zhou R, Pan D.

Rapid Commun Mass Spectrom. 2010 Sep;24(18):2765-75. doi: 10.1002/rcm.4703.

PMID:
20814984
13.

Loss of ARHGDIA expression is associated with poor prognosis in HCC and promotes invasion and metastasis of HCC cells.

Liang L, Li Q, Huang LY, Li DW, Wang YW, Li XX, Cai SJ.

Int J Oncol. 2014 Aug;45(2):659-66. doi: 10.3892/ijo.2014.2451. Epub 2014 May 21.

PMID:
24859471
14.

Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.

Lu LL, Sun J, Lai JJ, Jiang Y, Bai LH, Zhang LD.

World J Gastroenterol. 2015 Jun 7;21(21):6649-59. doi: 10.3748/wjg.v21.i21.6649.

15.

Analysis of the effects of microbiome-related confounding factors on the reproducibility of the volatolomic test.

Leja M, Amal H, Lasina I, Skapars R, Sivins A, Ancans G, Tolmanis I, Vanags A, Kupcinskas J, Ramonaite R, Khatib S, Bdarneh S, Natour R, Ashkar A, Haick H.

J Breath Res. 2016 Jun 24;10(3):037101. doi: 10.1088/1752-7155/10/3/037101.

PMID:
27341527
16.

Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.

Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB.

J Cancer Res Clin Oncol. 2000 Nov;126(11):641-6.

PMID:
11079728
17.

NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification.

Zhang Y, Fan Y, Mei Z.

Cancer Epidemiol. 2012 Oct;36(5):e294-9. doi: 10.1016/j.canep.2012.05.012. Epub 2012 Jun 23.

PMID:
22728279
18.

The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.

Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D.

Gut. 2012 Feb;61(2):278-89. doi: 10.1136/gut.2011.239145. Epub 2011 Jun 14.

PMID:
21672940
19.

Tiam1 is associated with hepatocellular carcinoma metastasis.

Huang J, Ye X, Guan J, Chen B, Li Q, Zheng X, Liu L, Wang S, Ding Y, Ding Y, Chen L.

Int J Cancer. 2013 Jan 1;132(1):90-100. doi: 10.1002/ijc.27627. Epub 2012 May 29. Erratum in: Int J Cancer. 2015 Oct 15;137(8):E14. Int J Cancer. 2015 Oct 15;137(8):E16.

20.

Differentiation between genetic mutations of breast cancer by breath volatolomics.

Barash O, Zhang W, Halpern JM, Hua QL, Pan YY, Kayal H, Khoury K, Liu H, Davies MP, Haick H.

Oncotarget. 2015 Dec 29;6(42):44864-76. doi: 10.18632/oncotarget.6269.

Supplemental Content

Support Center